Evidence mapPaperPMID 39446301Full record

ReviewMolecular biotechnology2025

Nanotechnology and CRISPR/Cas-Mediated Gene Therapy Strategies: Potential Role for Treating Genetic Disorders.

Guneet Kaur, Jasnoor Arora, Abhinashi Singh Sodhi, Sonu Bhatia, Navneet Batra

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Gene editing using gamma modified PNA: HBB gene as a model.Journal, genetic engineering & biotechnology · 2025
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Guneet Kaur *Department of Biotechnology, Goswami Ganesh Dutta Sanatan Dharma College, Sector-32-C, Chandigarh, 160030, India.
Jasnoor Arora *Department of Biotechnology, Goswami Ganesh Dutta Sanatan Dharma College, Sector-32-C, Chandigarh, 160030, India.
Abhinashi Singh SodhiDepartment of Biotechnology, Goswami Ganesh Dutta Sanatan Dharma College, Sector-32-C, Chandigarh, 160030, India.
Sonu BhatiaDepartment of Biotechnology, Goswami Ganesh Dutta Sanatan Dharma College, Sector-32-C, Chandigarh, 160030, India.
Navneet BatraDepartment of Biotechnology, Goswami Ganesh Dutta Sanatan Dharma College, Sector-32-C, Chandigarh, 160030, India. batranavneet@gmail.com.ORCID http://orcid.org/0000-0003-3765-6743

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gene therapy has made substantial progress in the treatment of the genetic diseases, focussing on the reduction of characteristics of recessive/dominant disorders, as well as various cancers. Extensive research has been conducted in the past few decades to investigate the application of nanotechnology and CRISPR/Cas technology in gene therapy. Nanotechnology due to attributes such has targeted drug delivery, controlled release, scalability and low toxicity has gained attention of the medical world. CRISPR/Cas9 system is considered as an impactful genome editing tool in the area of next-generation therapeutics and molecular diagnostics. CRISPR technology emphasises on gene editing, gene regulation modulation, and formulation of defined genetic changes. Its applications in treatment of the genetic disorders are extended beyond traditional therapies. These techniques are being explored as treatment of several genetic disorders including Duchenne muscular dystrophy, cystic fibrosis, Alzheimer's disease, Parkinson's disease, and Huntington disease. Despite considerable therapeutic potential of gene therapy, several obstacles must be addressed before it can be widely adopted in clinical practice, particularly in terms of ensuring safety and effectiveness. As research advances in this captivating field, these therapies will become the primary treatments and will have significant beneficial effects on the lives of patients with genetic disorders.

Indexed as

CRISPR-Cas SystemsGenetic Diseases, InbornGenetic TherapyNanotechnologyAnimalsGene EditingHumansMuscular Dystrophy, DuchenneCRISPR/CasDrug delivery systemsGene therapyGenetic disordersNanotechnologyNon-viral delivery

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.